Study S003207

Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0487-0111 in Participants With Various Degrees of Renal Impairment and Normal Renal Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06559527
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 42
Start: 2024-08-20
Primary completion: 2025-02-24
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2; Obesity; Overweight
Interventions: DRUG:NNC0487-0111
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1298-6886; OTHER:2023-509961-19; NIH:2023

Registered primary outcomes

AUC0111,0-∞,SD: Area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose [From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 28)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0029656	Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. Oldenburg LIK, Diabetes, obesity & metabolism	2026	Other trial	PMID 42443140 DOI	cites ClinicalTrials.gov:NCT06559527; registry reference DERIVED:42443140